Trials / Completed
CompletedNCT00161668
Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to assess the safety of Mylotarg therapy in routine practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mylotarg |
Timeline
- Start date
- 2001-10-01
- First posted
- 2005-09-12
- Last updated
- 2007-03-15
Locations
59 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00161668. Inclusion in this directory is not an endorsement.